The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke

Mary-Lou van Goor; Encarna Gómez García; Frank Leebeek; Geert-Jan Brouwers; Peter Koudstaal; Diederik Dippel

doi:10.1160/TH04-09-0560

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2005; 93(01): 92-96
DOI: 10.1160/TH04-09-0560

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke

A case-control study

Mary-Lou van Goor

¹Departments of Neurology, The Netherlands

,

Encarna Gómez García

²Hematology of the Erasmus Medical Center Rotterdam, The Netherlands

,

Frank Leebeek

²Hematology of the Erasmus Medical Center Rotterdam, The Netherlands

,

Geert-Jan Brouwers

²Hematology of the Erasmus Medical Center Rotterdam, The Netherlands

,

Peter Koudstaal

¹Departments of Neurology, The Netherlands

,

Diederik Dippel

¹Departments of Neurology, The Netherlands

› Institutsangaben

Abstract

Volltext

als PDF herunterladen

Keywords

PAI-1 4G/5G polymorphism - ischemic stroke - case-control - PAI-1 level

Referenzen

References
1 Ye S, Green FR, Scarabin PY. et al The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude Cas Temoins de I'nfarctus du Myocarde. Thromb Haemost 1995; 74: 837-41.
2 Catto AJ, Carter AM, Stickland M. et al Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost 1997; 77: 730-4.
3 Hamsten A, de Faire U, Walldius G. et al Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
4 Ny T, Sawdey M, Lawrence D. et al Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A 1986; 83: 6776-80.
5 Wiman B, Chmielewska J, Ranby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984; 259: 3644-7.
6 Strandberg L, Lawrence D, Ny T. The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family. Eur J Biochem 1988; 176: 609-16.
7 Dawson S, Hamsten A, Wiman B. et al Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11: 183-90.
8 Boekholdt SM, Bijsterveld NR, Moons AH. et al Genetic variation in coagulation and fibrinolytic pro- teins and their relation with acute myocardial infarction: a systematic review. Circulation 2001; 104: 3063-8.
9 Endler G, Lalouschek W, Exner M. et al The 4G/4G genotype at nucleotide position –675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol 2000; 110: 469-71.
10 Hindorff LA, Schwartz SM, Siscovick DS. et al The association of PAI-1 promoter 4G/5G insertion/ deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk 2002; 9: 131-7.
11 Hoekstra T, Geleijnse JM, Kluft C. et al 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke 2003; 34: 2822-8.
12 Roest M, van der Schouw YT, Banga JD. et al Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 2000; 101: 67-70.
13 Bang CO, Park HK, Ahn MY. et al 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue- type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis 2001; 11: 294-9.
14 Crainich P, Jenny NS, Tang Z. et al Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly. J Thromb Haemost 2003; 1: 1799-804.
15 Festa A, D'Agostino RA, Rich SS. et al Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, hispanics, and non-hispanic whites. Circulation 2003; 107: 2422-7.
16 Bamford J, Sandercock P, Dennis M. et al Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521-6.
17 Adams Jr. HP, Bendixen BH, Kappelle LJ. et al Classification of subtype of acute ischemic stroke. Stroke 1993; 24: 35-41.
18 Mahoney I F, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965; 14: 61-5.
19 Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977; 74: 5463-7.
20 Falk G, Almqvist A, Nordenhem A. Allele specific PCR for detection of a sequence polymorphism in the promotor region of the plasminogen activator inhibitor- 1 (PAI-1) gene. Fibrinolysis 1995; 9: 170-4.
21 Declerck PJ. Plasminogen activator inhibitor-1 (PAI-1) antigen. Laboratory techniques in thrombosis. A manual 2000; 239-45. (?¦ Title of manual).
22 Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995; 74: 1032-4.
23 Ridker PM, Hennekens CH, Lindpaintner K. et al Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95: 59-62.
24 Juhan-Vague I, Alessi M-C, Mavri A. et al Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-9.
25 Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2004; 342: 1792-801.